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A B S T R A C T
Duchenne muscular dystrophy (DMD) affects 1:3500–5000 newborn boys and manifests with progressive skeletal muscle wasting, respiratory failure and eventual
heart failure. Symptoms show different onset from patients' childhood to the second decade of age. We reprogrammed fibroblasts from two independent DMD
patients with a complete loss of dystrophin expression, carrying deletions of exons 45–50 and 48–50. The resulting hiPSCs show expression of pluripotency markers
(NANOG, OCT4, SSEA4), differentiation capacity into all three germ layers, normal karyotype, genetic identity to the originating parental fibroblasts and the patient-
specific dystrophin mutation.
Resource utility
Two human induced pluripotent stem cell (hiPSC) lines carrying
mutations in the DMD gene were generated to study the development of
Duchenne muscular dystrophy (DMD) in vitro, from a perspective of
stem cell damage and in perspective to the pathophysiology of the re-
sulting hiPSC-derived cardiomyocytes (CMs) and skeletal myotubes.
Resource details
DMD is an X-linked muscular degenerative disease which causes
progressive weakness and loss of ambulation in the early teen years
(Emery et al., 2015). Despite the progress of clinical care, heart failure
or respiratory failure lead to death by the end of the 2nd decade of life.
DMD is caused by mutations in the DMD gene coding dystrophin
protein leading to destabilization of the dystrophin glycoprotein com-
plex (DGC), with sarcolemmal instability, cell death, fibrosis and lipid
expansion in skeletal and cardiac muscles. Up to date, there is no
curative therapy for this condition. DMD-associated dilated cardio-
myopathy (DCM) is a major cause of mortality in affected patients and
requires dedicated investigation and realistic models. The most
common DMD model is the mdx mouse(Sicinski et al., 1989), although
the cardiac symptoms are mild and progress slowly, compared to hu-
mans relative to lifespan. Therefore, the mdx model carries major
limitations in cardiac disease modelling. Similarly, large animal models
like golden retriever muscular dystrophy (GRMD), canine X-linked
muscular dystrophy (CXMD), genetically engineered swine model, and
feline muscular dystrophy (HFMD) have severe limitations coming from
the animal physiology and variable cardiac involvement(Emery et al.,
2015).
To investigate the human DMD cardiac phenotype using a cellular
model, we generated patient-specific hiPSCs lines that were subse-
quently differentiated into cardiomyocytes. The informed consent
forms were obtained according to the Ethical Committee and Helsinki
declaration. Skin/muscle biopsies were harvested from two in-
dependent DMD boys (10- and 14-years old). From the biopsies, we
derived two hiPSC lines harbouring deletions in DMD gene spanning
exons 45–50 (DMD02, MUNIi001-A) and exons 48–50 (DMD03,
MUNIi003-A). Individual clones were chosen empirically based on
morphology. Selected clones from both lines tested positive for plur-
ipotent markers alkaline phosphatase, Nanog, Oct3/4, TRA1–81 and
SSEA4 (Fig. 1 A) and their expression pattern was comparable to wild
type (WT) hiPSC. Quantitative analysis of pluripotency markers'
mRNAs revealed similar expression of Oct4 and Nanog in both DMD
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hiPSC lines and WT control, while no expression was found in differ-
entiated human heart tissue (Fig. 2B). The ability of the generated DMD
hiPSC lines to differentiate in vitro into all three germ layers was tested
by incubation with ectodermal, endodermal or mesodermal inducing
medium (Fig. 1C). We observed an expression of early differentiation
markers of ectoderm (SOX1 in red, PAX6 in green), endoderm (SOX17
in green, FOXA2A in red) and mesoderm (GATA4 in green, brachyury in
red) in both DMD hiPSC lines. Multiplex ligation-dependent probe
amplification (MLPA) analysis showed the presence of the same mu-
tation in the DMD hiPSC lines (patient 1: deleted exons 45–50, referred
to as DMD02; and patient 2: deleted exons 48–50, referred to as
DMD03; Supplementary Table 1) and short tandem repeats analysis
confirmed their origin from the patient derived fibroblasts (data stored
with the editors). The obtained DMD hiPSC lines presented no dystro-
phin mRNA expression in pluripotent state compared to the WT hiPSC
(Fig. 1D, human heart sample used as positive control, human foreskin
fibroblasts used as negative control). Dystrophin absence was con-
firmed in CMs differentiated from DMD hiPSCs by western blot
(Jelinkova et al., 2019). All hiPSC derived CMs had positive signal for
cardiac troponin T as CM marker (Caluori et al., 2019) (two antibodies
recognizing N-terminus (N-ter) and C-terminus (C-ter) of dystrophin
protein were used, Fig. 1E). All hiPSC derived CMs had positive signal
for cardiac troponin T as CM marker. The generated hiPSC lines are
karyotypically healthy (both 46, XY, Supplementary files).
Materials and methods
Tissue processing
The fibroblasts of two DMD patients were derived from skin/muscle
(for DMD02/DMD03, respectively) biopsies. Informed consents ap-
proved by Ethics Committee (Faculty of Medicine, Masaryk University)
were signed by parents of the patients beforehand. The biopsy tissues
were cut into 0.5–1mm3 pieces, seeded onto 6 well plates (TPP) in
medium containing KnockOut DMEM (Invitrogen), 10% heat-in-
activated fetal bovine serum, 0,1 mM β-mercaptoethanol, 1% penicillin-
streptomycin, 1% L-glutamine, 1% non-essential amino acids and
layered with cover glasses. The tissue samples were kept in the in-
cubator for 5 days without movement. The medium was further
changed every 2–3 days and cells passaged at day 10 in vitro of culti-
vation using trypsin.
Pluripotent stem cell lines derivation and characterization
The hiPSC lines were obtained by reprogramming of cultivated
human fibroblasts using CytoTuneTM iPS reprogramming kit
(A13780–01; Life Technologies, Carlsbad, CA, USA) according to
manufacturer's recommendations. DMD hiPSC lines are referred to as
DMD02 (MUNIi001-A) and DMD03 (MUNIi003-A) and were further
cultivated either on feeder layer of mouse embryonic fibroblasts in
DMEM/F12, 15% KnockOut Serum replacement, 1% L-glutamine, 1%
non-essential amino acids (all Invitrogen, Carlsbad, CA, USA), 0,1 mM
β-mercaptoethanol (Sigma Aldrich, St.Louis, MO, USA) and 10 ng/ml
FGF2 (Peprotech, Rocky Hill, NJ, USA)] or on Matrigel™ (Corning, New
York, USA)-coated dish in feeder conditioned medium(Krutá et al.,
2014). DMD hiPSCs were characterized using immunocytochemical
staining of pluripotency markers (Nanog, Oct4, SSEA4, Alkaline phos-
phatase was tested using Blue Microwell Substrate kit AB0100 and
AB0200, Sigma Aldrich) and compared with wild type (WT) human
embryonic stem cell (hESC) line (Center for Cell Therapy line 14,
CCTL14)(Krutá et al., 2014). The ability of the DMD hiPSC lines to
differentiate in vitro into all three germ layers was tested by incubation
for:
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
MUNIi001-A DMD02 Male 10 Caucasian DMD Duchenne muscular dystrophy
MUNIi003-A DMD03 Male 14 Caucasian DMD Duchenne muscular dystrophy
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography normal Fig. 1, panel A
Phenotype Qualitative analysis (i.e.
Immunocytochemistry)
Assess staining/expression of pluripotency markers: Oct4,
Nanog, Sox2
Fig. 1 panel A
Quantitative analysis (i.e.
Immunocytochemistry counting, Flow
cytometry, RT-qPCR)
Assess % of positive cells or transcripts for antigen & cell
surface markers DMD03 Oct3/4: 98%, Nanog: 98%, SSEA-4:
99%
DMD02: Oct3/4: 97%, Nanog: 98%, SSEA-4: 99%
Fig. 1, panel A, calculated from ICC
images, Fig. 1 panel B as qPCR result
Genotype Karyotype (G-banding) and resolution Both 46XY,
Resolution 450–500
Fig. 1 panel F
Identity STR analysis DNA Profiling performed with 17 sites, matched submitted in archive with journal
Mutation analysis MLPA X-linked mutation on exons 45–50 (DMD02) /48–50 (DMD03) Supplementary Table 1
Microbiology and
virology
Mycoplasma Mycoplasma testing by luminescence. Negative Not shown, but available with
authors
Differentiation
potential
Directed differentiation ectodermal markers (SOX1 and PAX6), endodermal markers
(SOX17 and FOXA2A) and mesodermal markers (GATA4 and
brachyury) expression showed by ICC, plus successful
differentiation into CMs
Fig. 1 panel C and D
Donor screening HIV 1+2 Hepatitis B, Hepatitis C Negative N/A
Genotype additional
info
Blood group genotyping N/A N/A
HLA tissue typing HLA typed Class I and Class II N/A
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i) ectodermal induction: 2 days in RPMI1640, 1× B27, N2 supple-
ment (Gibco, Thermo Fisher Scientific) plus SB431542 (Sigma
Aldrich); 4 days in RPMI1640, 1× B27, N2 supplement
ii) endodermal induction: 6 days in RPMI1640 with B27, Activin A
50 ng/ml, BMP4 20 ng/ml, (both R&D)
iii) mesodermal induction: 3 days in RPMI1640 with B27, Activin A
10 ng/ml, BMP4 10 ng/ml; 1 day addition of IWP2 (Sigma Aldrich);
2 days in medium without IWP2.
Expression of early differentiation markers of ectoderm, endoderm
and mesoderm were detected in both DMD hiPSC lines after 6 days of
differentiation.
Immunocytochemistry
Cells were fixed with 2% paraformaldehyde for 15min and ice-cold
methanol for 5min, then permeabilized with 0.5% Triton X-100 and
blocked with 1% bovine serum albumin for 60min. Samples were in-
cubated overnight at 4 °C with appropriate primary antibodies and
60min at room temperature with secondary antibodies. Nuclei were
counterstained with 4′,6-diamidine-2′-phenylindole dihydrochloride
(DAPI, Sigma Aldrich, St. Louis, MO, USA) and microscopic images
were obtained using confocal microscope LSM700 and processed with
Zen system (both Carl Zeiss, Oberkrochen, Germany).
Mutation validation
DMD hiPSCs lines were tested for the mutation presence by clinical
MLPA analysis. MLPA was performed using SALSA MLPA P034 DMD
mix 1 probemix and SALSA MLPA P035 DMD mix 2 probemix (LOT
B1–1014, B1–0216, MRC Holland, Amsterdam, Netherlands), according
to manufacturer's instructions. MLPA fragments were separated on ABI
PRISM 3130 Genetic analyser (Applied Biosystems) and data were
analysed using Coffalyser software (MRC Holland).
PCR
Total mRNA from cell culture and human heart samples was lysed
using RNA Blue reagent (Top-Bio, Prague, Czech Republic) according to
the manufacturer's instructions, and the total mRNA was isolated using
the RNeasy Micro Kit (Qiagen, Hilden, Germany). mRNA concentration
and purity were determined using NanoDrop (NanoDrop technologies,
Wilmington, Germany). For reverse transcription PCR (rtPCR), cDNA
was synthesized by Moloney Mouse Leukemia Virus (M-MLV) reverse
transcriptase (Invitrogen, Carlsbad, CA, USA) at 37 °C for 1 h followed
by 5min at 85 °C. The consequent semi quantitative PCR was performed
using Taq polymerase (Top-Bio, T032, Prague Czech Republic) and
included denaturation at 95 °C for 10min followed by 35 cycles of 95 °C
for 10 s, annealing at 64 °C for 45 s and extension at 72 °C for 20 s; the
final extension step proceeded at 72 °C for 10min. For quantitative
PCR, LightCycler® 480 SYBR Green I Master kit was used according to
manufacturer's instructions. Annealing at 60 °C and 45 cycles were used
for the PCR reaction on LightCycler LC480 Instrument (both Roche,
Basil, Switzerland). The PCR primers (Generi-Biotech, Hradec Kralove,
Czech Republic) and annealing conditions are shown in Reagent Details
Table. The PCR product was then run on 1% agarose gel for 100min/
130 V/500mA and photos were obtained using UV lamp DNR MiniBis
Pro (Bio-Imaging Systems, Neve Yamin, Israel).
Line identity validation
Cell culture identity was analysed using short tandem repeat ana-
lysis using ABI PRISM 3130 Genetic analyser and PowerPlex® ESI17
Fast System (Promega) according to manufacturer's recommendations
(Tables 1 and 2).
Karyotype
Karyotypes were analysed in passages P83 (DMD02) and 59
(DMD03) (number indicates passage number on feeder layer) after in-
cubation with colchicine (2 μg/ml) for 4 h and treatment with hypo-
tonic solution consisting of cultivation medium and water in ratio 1:3.
Chromosome banding was achieved using Giemsa staining.
Chromosomes from 10 mitoses in each sample evaluated in resolution
400–450 bands. BX53 microscope (Olympus, Tokio, Japan) was used
with 1250× magnification and photos were taken using ProgRes MF
camera (Jenoptik, Jena, Germany). Images were evaluated using LUCIA
Cytogenetics 2 Karyo (Laboratory Imaging s.r.o., Prague, Czech
Republic).
Key resources table
Unique stem cell lines
identifier
MUNIi001-A
MUNIi003-A
Alternative names of st-
em cell lines
DMD02
DMD03
Institution Department of Biology, Faculty of Medicine, Masaryk
University, Brno 625 00, Czech Republic;
Contact information of
distributor
Vladimír Rotrekl PhD,vrotrekl@med.muni.cz
Type of cell lines hiPSC
Origin human
Cell Source Leg skin biopsy fibroblasts
Clonality mixed
Method of reprogram-
ming
Sendai virus
Multiline rationale Mutation in DMD gene with deletion of exons 45–50
(MUNIi001-A) or exons 48–50 (MUNIi003-A)
Gene modification Yes
Type of modification Hereditary
Associated disease Duchenne muscular dystrophy
Gene/locus Xp21
Method of modification N/A
Name of transgene or r-
esistance
N/A
Inducible/constitutive
system
N/A
Date archived/stock da-
te
MUNIi003-A 12.4.2015
MUNIi001-A 16.11.2015
Cell line repository/ba-
nk
https://hpscreg.eu/cell-line/MUNIi001-A
https://hpscreg.eu/cell-line/MUNIi003-A
Ethical approval Faculty of Medicine, Masaryk University Ethics Committee
(Brno, Czech Republic), approval number 37/2011
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2019.101562.
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